If you have established cardiovascular disease and meet criteria, note that semaglutide has evidence for cardiovascular risk reduction in people with overweight/obesity without diabetes
This includes structured intake questionnaires, health disclosures, and documentation tools that allow providers to evaluate eligibility for GLP-1 therapies without reliance on informal or fragmented data sources
Aoyama M, Kawase H, Bando YK, Monji A, Murohara T (2016) Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/Ras-related protein 1 axis
The drug has been shown to promote significant weight loss in both diabetic and non-diabetic individuals
With TrimRx, the process moves through three stages